Other News Releases in Biotechnology
DuPont Expects Strong 2010 Agriculture & Nutrition Sales Growth, Margin Expansion
QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
Other News Releases in Trade Show News
DuPont Expects Strong 2010 Agriculture & Nutrition Sales Growth, Margin Expansion
Invitation to the Tirol in the Austria House in Whistler Mountain
IKIVO Adds 3D and Hardware Acceleration to Mobile User Interfaces
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
See more news releases in: Biotechnology, Health Care & Hospitals, Trade Show News
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
SEATTLE, Oct. 29 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following upcoming investor conferences.
Merriman Investor Summit 2009
New York City
Tuesday, November 10, 2009
11:00 a.m. ET
Credit Suisse 2009 Healthcare Conference
Phoenix, Arizona
Friday, November 13, 2009
11:30 a.m. ET
Lazard Capital Markets 6th Annual Healthcare Conference
New York City
Tuesday, November 17, 2009
10:55 a.m. ET
The presentations will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.
SOURCE Dendreon Corporation
RELATED LINKS
http://www.dendreon.com